AdV-tk
ABTC-1603
Phase 1 mab completed
Quick answer
AdV-tk for Glioma, Malignant is a Phase 1 program (mab) at Candel Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Candel Therapeutics
- Indication
- Glioma, Malignant
- Phase
- Phase 1
- Modality
- mab
- Status
- completed